PTGS2 and colorectal carcinoma: Elevated expression of COX-2 has been detected in colorectal carcinoma (CRC) compared to normal mucosa and correlated with increased tumor size, angiogenesis, and invasiveness, providing the rationale for development of selective COX-2 inhibitors, such as celecoxib [2]–[5].